Next Article in Journal
Spatial Analysis of Drug-Resistant Tuberculosis in Colombia (2020–2023): Departmental Rates, Clusters, and Associated Factors
Previous Article in Journal
Concurrent Assessment of Synthetic and Natural Compounds on the Proliferation of Toxoplasma gondii in In Vitro Models
Previous Article in Special Issue
Molecular Mechanisms of Efficacy Variation in Antivenoms: Insights from a Malayan Pit Viper (Calloselasma rhodostoma) Bite in Vietnam
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Majeed et al. Mapping Evidence on the Regulations Affecting the Accessibility, Availability, and Management of Snake Antivenom Globally: A Scoping Review. Trop. Med. Infect. Dis. 2025, 10, 228

1
Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa
2
Department of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa
3
Department of Library Services, Sefako Makgatho Health Sciences, Pretoria 0204, South Africa
*
Author to whom correspondence should be addressed.
Trop. Med. Infect. Dis. 2025, 10(12), 350; https://doi.org/10.3390/tropicalmed10120350
Submission received: 27 November 2025 / Accepted: 1 December 2025 / Published: 15 December 2025
(This article belongs to the Special Issue Recent Advances in Snakebite Envenoming Research)
Error in Table
In the original publication [1], there was a mistake in Table 2, ‘Summary of the key findings corresponding to the emerging themes’. The original sentence with a mistake is ‘Lack of standardized treatment guidelines and commercial export policy in Africa’, which is in Column 2, Row 2. The corrected sentence is ‘Lack of commercial export policy in Africa’. The revised Table 2 is provided below.
Text Correction
There was an error in Section 3.3.1 (Regulatory frameworks), Paragraph 6.
The original sentence with a mistake is ‘The sole antivenom manufacturer in South Africa has no commercial export policy. Additionally, there are no national standardized SBE treatment guidelines [32–34].’ The corrected sentence is ‘The sole antivenom manufacturer in South Africa has no commercial export policy for public scrutiny, according to the included literature [32].’
References
Reference number 32 and 34 removed from the paper, so reference 33 in the original version should become 32 in the citation list at the end. Subsequent reference numbers are updated. With this correction, the order of some references has been adjusted accordingly.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Majeed, R.; Bester, J.; Kgarosi, K.; Strydom, M. Mapping Evidence on the Regulations Affecting the Accessibility, Availability, and Management of Snake Antivenom Globally: A Scoping Review. Trop. Med. Infect. Dis. 2025, 10, 228. [Google Scholar] [CrossRef] [PubMed]
Table 2. Summary of the key findings corresponding to the emerging themes.
Table 2. Summary of the key findings corresponding to the emerging themes.
ThemeKey Findings
Regulatory frameworks
  • Role of national health bodies in Latin America
  • Centralized and decentralized distribution systems
  • National programs in India and Thailand
  • Lack of commercial export policy in Africa
Manufacturing and procurement
  • High-income producers: USA, UK, Japan, Australia, and France
  • Latin America: Brazil, Costa Rica, Argentina, Colombia, and Mexico
  • Asia: India, Thailand, Indonesia, and Philippines
  • Africa: South Africa
Availability and access
  • Production cessation due to economic constraints
  • Usage of expired antivenom as an alternative resource
  • Impact of cold chain and storage problems on access
  • Poor health infrastructure and geographic inaccessibility
  • High costs
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Majeed, R.; Bester, J.; Kgarosi, K.; Strydom, M. Correction: Majeed et al. Mapping Evidence on the Regulations Affecting the Accessibility, Availability, and Management of Snake Antivenom Globally: A Scoping Review. Trop. Med. Infect. Dis. 2025, 10, 228. Trop. Med. Infect. Dis. 2025, 10, 350. https://doi.org/10.3390/tropicalmed10120350

AMA Style

Majeed R, Bester J, Kgarosi K, Strydom M. Correction: Majeed et al. Mapping Evidence on the Regulations Affecting the Accessibility, Availability, and Management of Snake Antivenom Globally: A Scoping Review. Trop. Med. Infect. Dis. 2025, 10, 228. Tropical Medicine and Infectious Disease. 2025; 10(12):350. https://doi.org/10.3390/tropicalmed10120350

Chicago/Turabian Style

Majeed, Ramsha, Janette Bester, Kabelo Kgarosi, and Morné Strydom. 2025. "Correction: Majeed et al. Mapping Evidence on the Regulations Affecting the Accessibility, Availability, and Management of Snake Antivenom Globally: A Scoping Review. Trop. Med. Infect. Dis. 2025, 10, 228" Tropical Medicine and Infectious Disease 10, no. 12: 350. https://doi.org/10.3390/tropicalmed10120350

APA Style

Majeed, R., Bester, J., Kgarosi, K., & Strydom, M. (2025). Correction: Majeed et al. Mapping Evidence on the Regulations Affecting the Accessibility, Availability, and Management of Snake Antivenom Globally: A Scoping Review. Trop. Med. Infect. Dis. 2025, 10, 228. Tropical Medicine and Infectious Disease, 10(12), 350. https://doi.org/10.3390/tropicalmed10120350

Article Metrics

Back to TopTop